Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

TY - JOUR

T1 - Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

AU - Ryom, L.

AU - Boesecke, C.

AU - Bracchi, M.

AU - Ambrosioni, J.

AU - Pozniak, A.

AU - Arribas, J.

AU - Behrens, G.

AU - Mallon, P. G.M.

AU - Puoti, M.

AU - Rauch, A.

AU - Miro, J. M.

AU - Kirk, O.

AU - Marzolini, C.

AU - Lundgren, J. D.

AU - Battegay, M.

AU - d'Arminio Monforte, Antonella

AU - Clumeck, Nathan

AU - Dedes, Nikos

AU - Gatell, José M.

AU - Horban, Andrzej

AU - Katlama, Christine

AU - McCormack, Sheena

AU - Molina, Jean Michel

AU - Mussini, Cristina

AU - Raffi, François

AU - Reiss, Peter

AU - Stellbrink, Hans Jürgen

AU - Bower, Mark

AU - Cinque, Paola

AU - Collins, Simon

AU - Compston, Juliet

AU - De Wit, Stéphane

AU - Fabbri, Leonardo M.

AU - Fux, Christoph A.

AU - Guaraldi, Giovanni

AU - Martínez, Esteban

AU - Papapoulos, Socrates

AU - du Pasquier, Renaud

AU - Poulter, Neil

AU - Williams, Ian

AU - Winston, Alan

AU - Berenguer, Juan

AU - Bhagani, Sanjay

AU - Bruno, Raffaele

AU - Konov, Svilen

AU - Lacombe, Karine

AU - Mauss, Stefan

AU - Mendão, Luís

AU - Peters, Lars

AU - Rockstroh, Jürgen K.

AU - the EACS Governing Board

PY - 2018

Y1 - 2018

N2 - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

AB - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

KW - antiretroviral treatment

KW - ART

KW - coinfections

KW - comorbidities

KW - European AIDS Clinical Society guidelines

KW - HBV

KW - HCV

KW - HIV

KW - opportunistic diseases

U2 - 10.1111/hiv.12600

DO - 10.1111/hiv.12600

M3 - Journal article

C2 - 29493093

AN - SCOPUS:85045475030

SN - 1464-2662

VL - 19

SP - 309

EP - 315

JO - HIV Medicine

JF - HIV Medicine

IS - 5

ER -